Morf Harriet, Witte Thorben
Medizinische Klinik 3 - Rheumatologie und Immunologie, Friedrich-Alexander Universität Erlangen-Nürnberg und Universitätsklinikum Erlangen, Ulmenweg 18, 91054, Erlangen, Deutschland.
Klinik für Rheumatologie und klinische Immunologie, Johannes Wesling Klinikum Minden, Minden, Deutschland.
Z Rheumatol. 2022 Mar;81(2):110-117. doi: 10.1007/s00393-021-01129-6. Epub 2021 Nov 26.
Biologics have been an integral part of the treatment of rheumatoid arthritis for approximately 20 years. As patents for pharmaceuticals generally expire after 10 years, in recent years biosimilars have come onto the market. Many studies have shown that they are an equivalent alternative to the reference drug with comparable safety and efficacy. In some cases, they even showed lower rates of adverse drug reactions compared to the reference drugs. Furthermore, considerable costs can be saved by biosimilars, which amount to an annual three-digit million sum in Germany alone. Large regional differences in the prescription frequency of biosimilars in Germany can be identified, which are also reflected in the savings potential. A switch to a biosimilar is possible and desirable with the involvement of the patient. In this sense, the initial prescription of a biosimilar instead of the reference drug is also to be advocated.
生物制剂在类风湿关节炎的治疗中已经应用了大约20年。由于药物专利通常在10年后到期，近年来生物类似药已进入市场。许多研究表明，它们是与参比药物等效的替代药物，具有相当的安全性和有效性。在某些情况下，与参比药物相比，它们甚至显示出更低的药物不良反应发生率。此外，生物类似药可以节省大量成本，仅在德国每年就达数百万欧元。在德国，可以发现生物类似药的处方频率存在很大的地区差异，这也反映在节省潜力上。在患者参与的情况下，改用生物类似药是可行且可取的。从这个意义上说，也提倡初始处方使用生物类似药而非参比药物。
